Quality of Life of Ghanaian Chronic Myeloid Leukaemia Patients on Tyrosine Kinase Inhibitors

被引：0
作者：
Kuma, A. Benneh-Akwasi [1 ,2 ]
Amponsah, E. [3 ]
Kyeremeh, R. [3 ]
Olayemi, E. [1 ,2 ]
机构：
[1] Univ Ghana, Haematol, Accra, Ghana
[2] Korle Bu Teaching Hosp, Accra, Ghana
[3] Univ Ghana, Med Lab Sci, Accra, Ghana
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
Chronic myeloid leukaemia; Ghana; Quality of Life; Tyrosine Kinase Inhibitor;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-PO-0
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [1] Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
    Anna Rychter
    Piotr Jerzmanowski
    Adam Hołub
    Zofia Specht-Szwoch
    Violetta Kalinowska
    Urszula Tęgowska
    Ilona Seferyńska
    Agnieszka Kołkowska-Leśniak
    Ewa Lech-Marańda
    Joanna Góra-Tybor
    Medical Oncology, 2017, 34
  • [2] Adherence assessment in Chronic Myeloid Leukaemia patients treated by tyrosine kinase inhibitors
    Daouphars, M.
    Ouvry, M.
    Lenain, P.
    Rouvet, J.
    Varin, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 414 - 415
  • [3] The effectiveness of tyrosine kinase inhibitors and molecular response in newly diagnosed patients of chronic myeloid leukaemia
    Fareed, N.
    Somroo, N. M.
    Quraishy, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 210 - 211
  • [4] Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors
    Piekarska, Agnieszka
    Gil, Lidia
    Jakitowicz, Karolina
    Prejzner, Witold
    Komarnicki, Mieczyslaw
    Hellmann, Andrzej
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (05): : 414 - 417
  • [5] Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukaemia and the occurrence of depressive symptoms
    Gibek, Katarzyna
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2023, 27 (04): : 277 - 283
  • [6] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Kristin M. Phillips
    Javier Pinilla-Ibarz
    Eduardo Sotomayor
    Morgan R. Lee
    Heather S. L. Jim
    Brent J. Small
    Lubomir Sokol
    Jeffrey Lancet
    Sara Tinsley
    Kendra Sweet
    Rami Komrokji
    Paul B. Jacobsen
    Supportive Care in Cancer, 2013, 21 : 1097 - 1103
  • [7] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Phillips, Kristin M.
    Pinilla-Ibarz, Javier
    Sotomayor, Eduardo
    Lee, Morgan R.
    Jim, Heather S. L.
    Small, Brent J.
    Sokol, Lubomir
    Lancet, Jeffrey
    Tinsley, Sara
    Sweet, Kendra
    Komrokji, Rami
    Jacobsen, Paul B.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (04) : 1097 - 1103
  • [8] Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Tinsley, Sara M.
    JOURNAL OF CLINICAL NURSING, 2010, 19 (9-10) : 1207 - 1218
  • [9] Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia
    Garcia, Betel Del Rosario
    Romero, Maria Micaela Vina
    Rosa, Virginia Gonzalez
    Payer, Carolina Alarcon
    Oliva, Leonor Oliva
    Merino Alonso, Francisco Javier Merino
    Casariego, Gloria Julia Nazco
    Nicolas, Fernando Gutierrez
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 902 - 906
  • [10] Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic
    Eskazan, Ahmet Emre
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1790 - 1792
12345